Preclinical dose number and its application in understanding drug absorption risk and formulation design for preclinical species

Molecular Pharmaceutics

Volumn 12, Issue 4, 2015, Pages 1031-1039

  Wuelfing, W Peter ^a   Daublain, Pierre ^a   Kesisoglou, Filippos ^a   Templeton, Allen ^a   McGregor, Caroline ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

AUC; dose number; dose proportionality; drug absorption; drug discovery; exposure; FaSSIF; formulation; preclinical; preclinical dose number; solubility

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; COMPUTER MODEL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DESIGN; DRUG EXPOSURE; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; EXPERIMENTAL DOG; EXPERIMENTAL MONKEY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRACTICE GUIDELINE; PRECLINICAL DOSE NUMBER; PRIORITY JOURNAL; ANIMAL; DOG; DRUG DEVELOPMENT; HAPLORHINI; HUMAN; INTESTINE ABSORPTION; MEDICINAL CHEMISTRY; PHARMACEUTICS; PHARMACOKINETICS; PROCEDURES; RAT; SOLUBILITY;

ANIMALS; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; DOGS; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HAPLORHINI; HUMANS; INTESTINAL ABSORPTION; PHARMACOKINETICS; RATS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 84926652126     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500504q     Document Type: Article

References (25)

1. Palucki, M.; Higgins, J.; Kwong, E.; Templeton, A. C. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates J. Med. Chem. 2010, 53, 5897-5905
2. Thakker, D. R. Strategic use of preclinical pharmacokinetics studies and in vitro models in optimizing ADME properties of lead compounds. In Optimizing the "Drug-Like" Properties of Leads in Drug Discovery; Borchardt, R. T.; Hageman, M. J.; Stevens, J. L.; Kerns, E. H.; Thakker, D. R., Eds; Springer: New York, 2006; Vol. IV, pp 1-24.
3. Gan, L.-S.; Lee, F. W.; Nelamangala, N.; Li, P.; Labutti, J.; Yin, W.; Xia, C.; Yang, H.; Uttamsingh, V.; Lu, C.; Pulsakar, S.; Daniels, J. S.; Huang, R.; Qian, M.; Wu, J.-T.; Cardoza, K.; Balani, S. K.; Miwa, G. T. Case history-use of ADME studies for optimization of drug candidates. In Optimizing the "Drug-Like" Properties of Leads in Drug Discovery; Borchardt, R. T.; Hageman, M. J.; Stevens, J. L.; Kerns, E. H.; Thakker, D. R., Eds; Springer: New York, 2006; Vol. IV, pp 81-98.
4. Hageman, M. J.; Solubility, solubilization and dissolution in drug delivery during lead optimization. In Optimizing the "Drug-Like" Properties of Leads in Drug Discovery; Borchardt, R. T.; Hageman, M. J.; Stevens, J. L.; Kerns, E. H.; Thakker, D. R., Eds; Springer: New York, 2006; Vol. IV, pp 99-130.
5. Caldwell, G. W. Compound optimization in early- and late-phase drug discovery; acceptable pharmacokinetic properties utilizing combined physicochemical in vitro and in vivo screens Curr. Opin. Drug Discovery Dev. 2000, 3, 30-41
6. Chen, X.-Q.; Antman, M. D.; Christoph, G.; Gudmundson, O. S. Discovery pharmaceutics-challenges and opportunities AAPS J. 2006, 8, E402-E407
7. Hilgers, A. R.; Smith, D. P.; Biermacher, J. J.; Day, J. S.; Jensen, J. L.; Sims, S. M.; Adams, W. J.; Fiis, J. M.; Palandra, J.; Hosley, J. D.; Shobe, E. M.; Burton, P. S. Predicting oral absorption of drugs: a case study with a novel class of antimicrobial agents Pharm. Res. 2003, 20, 1149-1155
8. Johnson, T. W.; Dress, K. R.; Edwards, M. Using the golden triangle to optimize clearance and oral absorption Biol. Med. Chem. Lett. 2009, 19, 5560-5564
9. Curatolo, W. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings Pharm. Sci. Technol. Today 1998, 74, 1255-1258
10. Sun, D.; Yu, L. X.; Hussain, M. A.; Wall, D. A.; Smith, R. L.; Amidon, G. L. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcomes Curr. Opin. Drug Discovery Dev. 2004, 7, 75-85
11. Gu, C.-H.; Li, H.; Levons, J.; Lentz, K.; Ganghi, R. B.; Raghavan, K.; Smith, R. L. Predicting effect of food on extent of absorption based on physicochemical properties Pharm. Res. 2007, 24, 1118-1130
12. Gao, Y.; Carr, R.; Spence, J. K.; Wang, W. W.; Turner, T. M.; Lipari, J. M.; Miller, J. M. A pH-dilution method for estimation of biorelevant drug solubility along the gastrointestinal tract: application to physiologically based pharmacokinetic modeling Mol. Pharmaceutics 2010, 5, 1516-1526
13. Bhattachar, S. N.; Perkins, E. J.; Tan, J. S.; Burns, L. J. Effect of gastric pH on the pharmacokinetics of a BCS class II compound in dogs: utilization of an artificial stomach and duodenum dissolution model and GastroPlus simulations to predict absorption J. Pharm. Sci. 2011, 11, 4756-4765
14. Kesisoglou, F. Use of preclinical dog studies and absorption modeling to facilitate late stage formulation bridging for a BCS II drug candidate AAPS PharmSciTech 2014, 15, 20-28
15. Kuentz, M.; Nick, S.; Parrott, N.; Rothlisberger, D. A strategy for preclinical formulation development using GastroPlusTM as pharmacokinetic simulation tool and a statistical screening design applied to a dog study Eur. J. Pharm. Sci. 2006, 27, 91-99
16. Wuelfing, W. P.; Kwong, E. K.; Higgins, J. P. Identification of suitable formulations for high dose oral studies in rats using in vitro solubility measurements, the maximum absorbable dose model, and historical data sets Mol. Pharmaceutics 2012, 9, 1163-1174
17. Oh, D. M.; Curl, R.; Amidon, G. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model Pharm. Res. 1993, 10, 264-270
18. Martinez, M.; Amidon, G. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals J. Clin. Pharmacol. 2002, 42, 620-643
19. Dahan, A.; Miller, J.; Amidon, G. L. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs AAPS J. 2009, 11, 740-746
20. Rohrs, B. R. Biopharmaceutics modeling and the role of dose and formulation on oral exposure. In Optimizing the "Drug-Like" Properties of Leads in Drug Discovery; Borchardt, R. T.; Hageman, M. J.; Stevens, J. L.; Kerns, E. H.; Thakker, D. R., Eds; Springer: New York, 2006; Vol. IV, pp 151-166.
21. Sugano, K.; Okazaki, A.; Sugimoto, S. Solubility and dissolution profile assessment in drug discovery Drug Metab. Pharmacokinet. 2007, 22, 225-254
22. Dressman, J. B.; Amidon, G. L.; Reppas, C.; Shah, V. P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release oral dosage forms J. Pharm. Sci. 1998, 1, 11-22
23. Sugano, K. Computational oral absorption simulation for low-solubility compounds Chem. Biodiversity 2009, 6, 2014-2029
24. Kararli, T. T. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals Biopharm. Drug Dispos. 1995, 16, 351-380
25. Mota, F. L.; Carneiro, A. P.; Queimada, A. J.; Pinho, S. P.; Macedo, E. A. Temperature and solvent effects in the solubility of some pharmaceutical compounds: measurements and modeling Eur. J. Pharm. Sci. 2009, 37, 499-507